2025-10-24 - Analysis Report
Okay, here's an analysis of Schrodinger Inc. (SDGR) based on the provided data.  I'll provide numbers first, followed by analysis.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** SDGR
*   **Company:** Schrodinger Inc. (A company focusing on computational chemistry software and services).
*   **SDGR Cumulative Return:** -49.89%
*   **VOO Cumulative Return:** 67.25%
*   **Absolute Divergence (Current):** -118.9
*   **Divergence Range (Max/Min):** 42.2 / -120.9
*   **Relative Divergence:** 1.2

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2020-2022  | -70.0% | 78.2% | -76.0% | 0.0   | 1.4    |
| 2021-2023  | -57.0% | 81.0% | -59.0% | -0.0  | 2.8    |
| 2022-2024  | 6.0%   | 81.0% | -14.0% | -0.0  | 1.5    |
| 2023-2025  | 2.0%   | 82.6% | -62.0% | -0.0  | 1.6    |

**Analysis (Performance vs. S&P 500):**

SDGR has significantly underperformed the S&P 500 (VOO) over the period examined. The cumulative return difference is substantial (-118.9). The relative divergence of 1.2 suggests that SDGR is currently near the bottom of its historical divergence range compared to the S&P 500.  The Alpha/Beta analysis shows negative alpha across all periods, indicating underperformance relative to the market. The beta values are near zero, suggesting very low correlation with the market.  The negative CAGR and high MDD values indicate high volatility and significant losses over the periods analyzed.

**2. Recent Price Action**

*   **Current Price:** 20.87
*   **Last Market Data:** {'price': 21.96, 'previousClose': 20.79, 'change': 5.63}
*   **5-Day Moving Average:** 20.616
*   **20-Day Moving Average:** 20.1537
*   **60-Day Moving Average:** 19.6806

**Analysis (Recent Price Action):**

The stock is trading above its 5, 20, and 60-day moving averages, which *could* indicate a short-term uptrend. The "Last Market Data" showing a significant price increase suggests a potential recent positive catalyst. The price jumped 5.63% to 21.96, indicating some positive momentum, but it closed down to 20.87 at closing.

**3. Market Risk Indicator (MRI) & Other Indicators**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 48.62
*   **PPO:** 0.449
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (47 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** -1.7 (Negative - Short-term decline)
*   **Expected Return (%):** -5132.9 (Long-term, relative to S&P 500)

**Analysis (MRI & Other Indicators):**

The MRI of 0.9 suggests a high investment recommendation based on the model, which seems contradictory given the other negative indicators. The RSI is neutral. The PPO is slightly positive but not significantly. The Hybrid Signal recommends buying, but this seems overly optimistic given the overall picture. The negative change in relative divergence suggests short-term underperformance is continuing. The extremely negative expected return suggests the model forecasts significant underperformance relative to the S&P 500 over the long term.

**4. Recent News & Significant Events:**

*   **Oct 22, 2025:** Q3 2025 Earnings Announcement on November 5
*   **Oct 21, 2025:** Strength Seen in Schrodinger (SDGR) - Zacks article highlighting a potential further increase.
*   **Oct 15, 2025:** Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
*   **Sept 11, 2025:** Evaluating Valuation as Market Sentiment Remains Quiet
*   **Sept 09, 2025:** Potential to Rally 40.43% - Wall Street Analyst Expectation
*   **Aug 27, 2025:** Presentation at Morgan Stanley Global Healthcare Conference

**Analysis (Recent News):**

The news is a mixed bag. The upcoming earnings announcement is a key event. The Zacks article suggesting potential strength is positive. The inducement grants are a typical corporate event. The articles from September suggest uncertainty about valuation and potential upside.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (~1.56)
*   **Target Price (Avg/High/Low):** 27.00 / 33.00 / 19.00
*   **Recent Rating Changes:** (Not specified, but implies no recent changes).

**Analysis (Analyst Opinions):**

Despite the poor performance, analysts generally have a "Buy" rating on the stock with an average target price of $27, suggesting significant upside potential from the current price. However, it's crucial to understand *why* analysts are bullish despite the poor performance. It is vital to see the analysts report to see why they give this buy recommendation.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출     |
|------------|--------|----------|
| 2025-08-06 | -0.59 | 0.05 B$  |
| 2025-05-07 | -0.82 | 0.06 B$  |
| 2024-11-12 | -0.52 | 0.04 B$  |
| 2024-07-31 | -0.74 | 0.05 B$  |
| 2025-08-06 | -0.74 | 0.05 B$  |

**Analysis (Recent Earnings):**

Schrodinger has consistently reported negative EPS figures. Revenue has been relatively stable, around $0.05 Billion per quarter. The continued losses are a concern.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |
| 2024-06-30 | $0.05B  | 66.20%        |

**Capital and Profitability:**

| Quarter    | Equity | ROE      |
|------------|--------|----------|
| 2025-06-30 | $0.34B | -12.59%  |
| 2025-03-31 | $0.37B | -16.01%  |
| 2024-12-31 | $0.42B | -9.54%   |
| 2024-09-30 | $0.45B | -8.49%   |
| 2024-06-30 | $0.47B | -11.40%  |

**Analysis (Financial Information):**

Revenue is volatile but relatively consistent. Profit margins are positive, which is good, but not enough to offset expenses and generate overall profitability. Equity is declining, and ROE is consistently negative, reflecting the company's inability to generate profits from its equity.

**7. Overall Summary & Conclusion:**

Schrodinger (SDGR) is a company with significant challenges. It has severely underperformed the market, has negative profitability, and declining equity. While analysts have a "Buy" rating, this seems disconnected from the underlying financial performance.

*   **Bearish Signals:**
    *   Significant underperformance vs. S&P 500
    *   Negative Alpha, CAGR, and ROE.
    *   Consistently negative EPS.
    *   Declining equity.
    *   Negative long-term expected return.
*   **Potentially Bullish Signals:**
    *   Recent positive price action (but needs to be sustained).
    *   Analyst "Buy" ratings (but requires further investigation).
    *   High MRI (but seems inconsistent with other data).

**Recommendation:**

Based on the data provided, a cautious approach is warranted. The "Buy" ratings from analysts should be carefully examined to understand their rationale. The recent positive price action is encouraging, but it's too early to tell if it represents a sustained trend. Given the company's financial challenges, significant due diligence is required before considering an investment. The negative long-term expected return should be a significant red flag. The MRI score may be inaccurate so further investigation is needed to verify the score.

In short, the data paints a concerning picture, and I would advise caution.
